Opinion

Video

Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Author(s):

Adam M. Brufsky, MD, PhD,Erika P. Hamilton, MD

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

Related Videos
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
1 expert in this video
1 expert in this video
David Rimm, MD, PhD
Vered Stearns, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
1 expert in this video
1 expert in this video
Related Content
November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Breast Cancer
November 27th 2024

Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Jairam Krishnamurthy, MD, FACP
November 22nd 2024

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center
November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers